真培美曲塞或长春瑞滨联合顺铂治疗晚期肺腺癌的效果比较

目的: 比较长春瑞滨或培美曲塞联合顺铂治疗晚期肺腺癌的临床疗效及毒副作用。方法: 晚期肺腺癌53例随机分为长春瑞滨加顺铂组(NC组)27例和培美曲塞加顺铂组(PC组)29例。NC组:长春瑞滨25 mg/m2,第1、8天;顺铂25 mg/m2,第2~4天。PC组:培美曲塞500 mg/m2,第1天;顺铂25 mg/m2,第2~4天,每3周为一个周期重复,2周期后评价疗效。结果: NC组和PC组有效率分别为41.67%和51.72%,2组差异无统计学意义(P > 0.05)。PC组脉管炎发生率为6.90%,低于NC组的37.50%(P < 0.05),其他的不良反应能耐受。结论: 培美曲塞与长春瑞滨联合顺铂治疗晚期肺腺癌的疗效一致,不良反应少,容易耐受,可以考虑作为肺腺癌临床一线治疗方案之一。

Efficacy and toxicity of pemetrexed or vinorelbine plus cisplatin in treatment of patients with adenocarcinoma of lung

Objective:To observe the efficacy and toxicity of pemetrexed or vinorelbine plus cisplatin in treatment of patientswith adenocarcinoma of lung.Methods:The 53 cases of advanced adenocarcinoma lung were divided into vinorelbine plus cisplatin group(NC= 27) and pemetrexed plus cisplatin group(PC group) in 29 cases.NC group:vinorelbine 25 mg/m2,days 1,8;cisplatin 25 mg/m2,2 to 4 days.PC group:pemetrexed 500 mg/m2,d day 1;cisplatin 25 mg/m2,2 to 4 days,every 3 weeks for a period of repeated,two cycles were evalu...